Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LPTX
stocks logo

LPTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.200
-45.95%
--
--
-0.120
-67.57%
--
--
-0.120
-70%
Estimates Revision
The market is revising No Change the revenue expectations for Leap Therapeutics, Inc. (LPTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 624.38%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+624.38%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Leap Therapeutics Inc (LPTX.O) is -3.01, compared to its 5-year average forward P/E of -2.32. For a more detailed relative valuation and DCF analysis to assess Leap Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.32
Current PE
-3.01
Overvalued PE
-0.67
Undervalued PE
-3.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
37.71
Current PS
2.05
Overvalued PS
88.93
Undervalued PS
-13.52
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LPTX News & Events

Events Timeline

(ET)
2025-11-12
07:08:55
Leap Therapeutics Rebrands as 'Cypherpunk Technologies,' Adopts 'CYPH' Ticker
select
2025-10-20 (ET)
2025-10-20
07:08:23
Leap Therapeutics announces findings from Phase 2 trial of sirexatamab
select
2025-06-23 (ET)
2025-06-23
07:03:32
Leap Therapeutics reports updated results from Phase B of DeFianCe study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-13TipRanks
Three Penny Stocks to Keep an Eye on as of November 13, 2025

  • Penny Stocks to Watch: Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are highlighted as key penny stocks to monitor on November 13, 2025, based on their Dollar Volume and market activity.

  • Leap Therapeutics Update: Leap Therapeutics (LPTX) experienced a significant stock price increase of over 368% after announcing plans to expand into digital asset investments and rebranding to "Cypherpunk Technologies" (CYPH).

  • Amaze Holdings Acquisition: Amaze Holdings (AMZE) saw a nearly 17% drop in stock price despite acquiring The Food Channel's assets for $650,000, aiming to enhance its creator-powered commerce platform.

  • Salarius Pharmaceuticals Recovery: Salarius Pharmaceuticals (SLRX) had a 17.4% stock price gain following a public offering to raise $7 million for research and debt repayment, reversing a previous 51% drop.

[object Object]
Preview
2.0
11-13TipRanks
Unpacking the Astonishing Surge in Leap Therapeutics Stock (LPTX)

  • Stock Surge and Rebranding: Leap Therapeutics (LPTX) experienced a 368.6% stock surge after announcing a strategic shift towards digital asset investments and a rebranding to Cypherpunk Technologies, with a new ticker symbol CYPH.

  • Digital Asset Strategy: The company revealed a digital asset treasury strategy focused on accumulating Zcash (ZEC), using $50 million from a private placement to acquire 203,775 ZEC tokens, emphasizing its commitment to privacy-focused cryptocurrencies.

  • Financial Performance: For Q3 2025, Leap Therapeutics reported a net loss of $3.3 million, significantly reduced from $18.2 million in Q3 2024, attributed to lower expenses following workforce reductions and completed clinical trials.

  • Future Plans: The company aims to continue developing its cancer treatments while advancing its digital asset strategy, utilizing recent capital raises to support both biotech operations and digital initiatives, despite currently having no Wall Street coverage.

[object Object]
Preview
2.0
11-13Benzinga
Crude Oil Falls 4%; Shares of Holding Companies Surge Following Q3 Earnings Report

  • Market Performance: U.S. stocks showed mixed results, with the Dow rising 0.66% while the Nasdaq fell 0.65% and the S&P 500 dropped 0.13%. Health care shares increased by 1.1%, but communication services stocks fell by 1.7%.

  • Notable Stock Movements: On Holding's shares surged over 18% after reporting strong earnings, while Leap Therapeutics saw a 145% increase. Conversely, VisionSys AI's shares plummeted 77% following a direct offering announcement.

  • Commodity Trends: Oil prices decreased by 4.1% to $58.51, while gold rose by 2% to $4,199.90. Silver and copper also saw gains of 4.7% and 1.1%, respectively.

  • Global Market Overview: European shares rose, with the eurozone's STOXX 600 up 0.71%, and Asian markets mostly closed higher, led by Japan's Nikkei 225 and Hong Kong's Hang Seng.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Leap Therapeutics Inc (LPTX) stock price today?

The current price of LPTX is 1.7 USD — it has increased 78.63 % in the last trading day.

arrow icon

What is Leap Therapeutics Inc (LPTX)'s business?

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

arrow icon

What is the price predicton of LPTX Stock?

Wall Street analysts forecast LPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPTX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Leap Therapeutics Inc (LPTX)'s revenue for the last quarter?

Leap Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Leap Therapeutics Inc (LPTX)'s earnings per share (EPS) for the last quarter?

Leap Therapeutics Inc. EPS for the last quarter amounts to -0.08 USD, decreased -81.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Leap Therapeutics Inc (LPTX)'s fundamentals?

The market is revising No Change the revenue expectations for Leap Therapeutics, Inc. (LPTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 624.38%.
arrow icon

How many employees does Leap Therapeutics Inc (LPTX). have?

Leap Therapeutics Inc (LPTX) has 52 emplpoyees as of December 06 2025.

arrow icon

What is Leap Therapeutics Inc (LPTX) market cap?

Today LPTX has the market capitalization of 67.73M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free